Molecular Response of 10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC TrialJane Apperley,Jorge Cortes,Elias Jabbour,Andreas Hochhaus,Timothy Hughes,Charles Chuah,Hugues de Lavallade,Michael Deininger,Jeffrey H. Lipton,Elza Lomaia,Lori Maness,Michael Mauro,James McCloskey,Beatriz Moiraghi,Carolina Pavlovsky,Christine Rojas,Philippe Rousselot,Tomasz Sacha,Moshe Talpaz,Anna Turkina,Maria Undurraga Sutton,Xiaowei Ren,Alexander Vorog,Gianantonio RostiBlood（2023）引用 1|浏览15暂无评分关键词BCR::ABL1, CP-CML, ponatinib, TKIAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
